What is 4D Molecular Therapeutics's G&A?

4D Molecular Therapeutics (FDMT) reported G&A of $11.69M in Q1 2026.

How has 4D Molecular Therapeutics's G&A changed year-over-year?

4D Molecular Therapeutics's G&A decreased by 9.7% year-over-year, from $12.94M to $11.69M.

What is the long-term trend for 4D Molecular Therapeutics's G&A?

Over 4 years (2021 to 2025), 4D Molecular Therapeutics's G&A has grown at a 15.0% compound annual growth rate (CAGR), from $28.01M to $49.06M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

4D Molecular Therapeutics FDMT G&A

G&A at other companies

EyePoint, Inc. EYPT

$15.24M+9.9%

RegenxbioRGNX

$21.31M+4.7%

MeiraGTx Holdings plcMGTX

$8.93M-4.7%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

Kodiak Sciences IncKOD

$11.23M-27.2%

Design Therapeutics, Inc.DSGN

$5.33M+5.7%

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's G&A?: 4D Molecular Therapeutics (FDMT) reported G&A of $11.69M in Q1 2026.
How has 4D Molecular Therapeutics's G&A changed year-over-year?: 4D Molecular Therapeutics's G&A decreased by 9.7% year-over-year, from $12.94M to $11.69M.
What is the long-term trend for 4D Molecular Therapeutics's G&A?: Over 4 years (2021 to 2025), 4D Molecular Therapeutics's G&A has grown at a 15.0% compound annual growth rate (CAGR), from $28.01M to $49.06M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.